ERBB2 and gastroesophageal junction adenocarcinoma: We identified 3 clinical trials that randomly assigned patients with Her-2 negative G or GEJ adenocarcinomas with disease control following completion of first-line chemotherapy (Table  3; Supplementary Tables 3 and 4, available online).